
## Guangsen Han

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4327036/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: Updated results of efficacy and safety Journal of Clinical Oncology, 2021, 39, 4036-4036.	1.6	11
2	MiR-27b suppresses epithelial–mesenchymal transition and chemoresistance in lung cancer by targeting Snail1. Life Sciences, 2020, 254, 117238.	4.3	28
3	LINC00667/miR-449b-5p/YY1 axis promotes cell proliferation and migration in colorectal cancer. Cancer Cell International, 2020, 20, 322.	4.1	21
4	Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma Journal of Clinical Oncology, 2020, 38, 4536-4536.	1.6	13
5	Increased H. pylori stool shedding and EPIYA-D cagA alleles are associated with gastric cancer in an East Asian hospital. PLoS ONE, 2018, 13, e0202925.	2.5	12
6	A meta-analysis of prognostic value of KIT mutation status in gastrointestinal stromal tumors. OncoTargets and Therapy, 2016, 9, 3387.	2.0	7
7	MALAT1 might be a predictive marker of poor prognosis in patients who underwent radical resection of middle thoracic esophageal squamous cell carcinoma. Cancer Biomarkers, 2015, 15, 717-723.	1.7	37
8	Clinical research of superior mesenteric vascular intrathecal approach in right hemicolectomy. Chinese-German Journal of Clinical Oncology, 2010, 9, 633-636.	0.1	1